Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivec™) for Advanced Stage Gastrointestinal Stromal Tumours

Skin toxicity is a common side-effect of treatment with imatinib mesylate (STI571, Glivec™) in advanced gastrointestinal stromal tumours (GIST) and chronic myeloid leukaemia. The optimal duration of treatment with imatinib mesylate in GIST has not yet been established, as durable remissions have bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Lucy C., White, Jeff D., Reid, Robin, Cowie, Fiona
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395637/
https://www.ncbi.nlm.nih.gov/pubmed/18521425
http://dx.doi.org/10.1080/13577140500349717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395637/
https://www.ncbi.nlm.nih.gov/pubmed/18521425
http://dx.doi.org/10.1080/13577140500349717

Ejemplares similares